Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Sponsor
Sun Yat-sen University
Study ID
NCT02867956
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
  • Etoposide — DRUG
    Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles

Study Details

The purpose of the study is to evaluate the efficacy and toxicity of apatinib in patients with platinum resistant or refractory ovarian cancer when combined with etoposide.

Key Dates

Start date
Aug 10, 2016
Status verified
Mar 2026
Primary completion
Dec 31, 2017
Completion
Sep 10, 2019

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib + Etoposide
    Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles.

Primary Outcome Measure

Objective response rate [ Time Frame: Up to three years ]

Related Studies